Sugi Predict

Sugi Predict / Compounds / SCHEMBL4852041

SCHEMBL4852041

SCHEMBL4852041

CN(CCC(O)c1ccccc1)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CARM1 Q86X55 1/20 0.53
▸ PRMT6 Q96LA8 1/20 0.53
▸ PRMT8 Q9NR22 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SIGMAR1 Q99720 2/20 0.49
▸ TAAR1 Q96RJ0 1/20 0.48
▸ RIPK1 Q13546 1/20 0.47
▸ AOC3 Q16853 1/20 0.47
▸ CNR2 P34972 1/20 0.46
▸ LMNA P02545 2/20 0.46
▸ TSHR P16473 3/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ MAOB P27338 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ MAOA P21397 1/20 0.43
▸ PYCR1 P32322 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8297797 0.84 HTR2A (0.62) CARM1PRMT6PRMT8SMN1; SMN2KDM4E
SCHEMBL8080511 0.84 AOC3 (0.54) MEN1KMT2ASIGMAR1AOC3TSHR
SCHEMBL19746594 0.82 CARM1 (0.56) CARM1PRMT6PRMT8SMN1; SMN2SIGMAR1
SCHEMBL15120372 0.82 LMNA (0.53) KDM4ESIGMAR1TAAR1RIPK1AOC3
SCHEMBL5478551 0.82 CARM1 (0.56) CARM1PRMT6PRMT8SMN1; SMN2SIGMAR1
SCHEMBL13993320 0.82 KDM4E (0.70) CARM1PRMT6PRMT8SMN1; SMN2KDM4E
SCHEMBL14274010 0.82 KDM4E (0.70) CARM1PRMT6PRMT8SMN1; SMN2KDM4E
SCHEMBL11237204 0.82 RIPK1 (0.46) SMN1; SMN2KDM4EMEN1KMT2ATAAR1
SCHEMBL28339091 0.82 KDM4E (0.70) CARM1PRMT6PRMT8SMN1; SMN2KDM4E
SCHEMBL14356718 0.82 RIPK1 (0.46) SMN1; SMN2KDM4EMEN1KMT2ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1948276-B Improved preparation method of flurazetin UNIV EAST CHINA SCIENCE & TECH 2010-05-12 — — CN claimed
CN-1948276-B Improved preparation method of flurazetin UNIV EAST CHINA SCIENCE & TECH 2010-05-12 — — CN disclosed
CN-100430370-C Propylamine derivative and its application in preparing tomocetin UNIV HUADONG TECHNOLOGY (CN) 2008-11-05 — — CN disclosed
US-7410982-B2 Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors ELI LILLY AND COMPANY (US) 2008-08-12 — — US disclosed
US-7410982-B2 Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors ELI LILLY AND COMPANY (US) 2008-08-12 — — US disclosed
US-7410982-B2 Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors ELI LILLY AND COMPANY (US) 2008-08-12 — — US disclosed
CN-1948277-A Propylamine derivative and its application in preparing tomocetin UNIV HUADONG TECHNOLOGY (CN) 2007-04-18 — — CN disclosed
CN-1948276-A Improved preparation method of flurazetin HUADONG UNVI OF TECHNOLOGY (CN) 2007-04-18 — — CN disclosed
WO-2007009405-A1 A METHOD FOR THE PREPARATION OF (R)-N-METHYL-3-(2-METHYLPHENOXY)-3-PHENYLPROPYLAMINE HYDROCHLORIDE (ATOMOXETINE) ZENTIVA, A.S. (CZ) 2007-01-25 — — WO disclosed
EP-1567501-B1 PROPANAMINE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS LILLY CO ELI (US) 2006-10-25 — — EP disclosed
US-20040176435-A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors ELI LILLY AND COMPANY 2004-09-09 — — US disclosed
EP-1397129-A1 HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2004-03-17 — — EP disclosed
WO-2002094262-A1 HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2002-11-28 — — WO disclosed
EP-0929514-A1 PROCESS FOR THE PREPARATION OF FLUOXETINE EGIS GYOGYSZERGYAR RT. (HU) 1999-07-21 — — EP disclosed
EP-0617006-B1 N-Substituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine and procedure for their preparation PLIVA PHARM & CHEM WORKS (HR) 1998-05-06 — — EP disclosed
WO-1998011054-A1 PROCESS FOR THE PREPARATION OF FLUOXETINE EGIS Gyógyszergyár Rt. (HU) 1998-03-19 — — WO disclosed
US-5618968-A N-substituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine and the procedure for their preparation PLIVA FARMACEUTSKA KEMIJSKA, PREHRAMBENA I KOZMETICKA INDUSTRIJA, DIONICKO DRUSTVO (HR) 1997-04-08 — — US disclosed
EP-0617006-A1 N-subtituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine and the procedure for their preparation PLIVA d.d. ZAGREB (HR) 1994-09-28 — — EP disclosed
EP-0373836-B1 Improvements in or relating to serotonin and norepinephrine uptake inhibitors LILLY CO ELI (US) 1994-03-16 — — EP disclosed
US-4902710-A THIO-, SULFINYL-, OR SULFONYL-PROPANAMINES; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS; NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY (US) 1990-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176435-A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors ADRA2C, ADRB1, TPH1 CARM1 2339/4885PRMT6 3627/4885PRMT8 4034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.